{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:28:06Z","timestamp":1759336086649,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008540","name":"Fundacion Cajamurcia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.humimm.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:49:39Z","timestamp":1623458979000},"page":"621-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relationship between polymorphisms in the FAS\/FASL death receptor system and progression of low-grade precursor lesions infected with high-risk human papilloma virus"],"prefix":"10.1016","volume":"82","author":[{"given":"Vicente","family":"Santaclara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Torres-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen M.","family":"Bernal-Ma\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Alejandra","family":"Isaac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Ortiz-Reina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-3044","authenticated-orcid":false,"given":"Pablo","family":"Conesa-Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrmicro1066","article-title":"Viral modulation of NK cell immunity","volume":"3","author":"Lodoen","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"issue":"4","key":"10.1016\/j.humimm.2021.06.002_b0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2011.06.069","article-title":"Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C","volume":"141","author":"Ahlenstiel","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1756-8722-2-50","article-title":"New targets for the treatment of follicular lymphoma","volume":"2","author":"Tageja","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.humimm.2021.06.002_b0020","doi-asserted-by":"crossref","unstructured":"Zhu J, Powis De Tenbossche CG, Can\u00e9 S, Colau D, Van Baren N, Lurquin C, et al, Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes, Nat Commun 2017;8:1404.","DOI":"10.1038\/s41467-017-00784-1"},{"issue":"5","key":"10.1016\/j.humimm.2021.06.002_b0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00262-018-2269-y","article-title":"Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism","volume":"68","author":"Zhu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2334-9-124","article-title":"Genotype distribution of human papillomavirus (HPV) and coinfections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain","volume":"9","author":"Conesa-Zamora","year":"2009","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.humimm.2021.06.002_b0035","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"Forum group members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0040","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0463.2008.00009.x","article-title":"A type-specific study of human papillomavirus prevalence in cervicovaginal samples in three different Spanish regions","volume":"117","author":"Gomez-Roman","year":"2009","journal-title":"APMIS"},{"issue":"6","key":"10.1016\/j.humimm.2021.06.002_b0045","doi-asserted-by":"crossref","first-page":"E305","DOI":"10.1002\/ajh.24354","article-title":"A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients","volume":"91","author":"Guti\u00e9rrez-C\u00edvicos","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.humimm.2021.06.002_b0050","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.humimm.2013.07.006","article-title":"Evaluation of the association of NKG2C copy number variations with susceptibility to human papillomavirus-induced cervical lesions","volume":"74","author":"Vilchez","year":"2013","journal-title":"Hum. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2021.06.002_b0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ijc.10800","article-title":"Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis","volume":"103","author":"Lai","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2005.04.001","article-title":"Fas gene promoter -670 polymorphism (A\/G) is associated with cervical carcinogenesis","volume":"98","author":"Ueda","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.humimm.2021.06.002_b0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.humimm.2021.06.002_b0070","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1309\/AJCPO0WY1VIFCYDC","article-title":"Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study","volume":"132","author":"Conesa-Zamora","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.humimm.2021.06.002_b0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/CS20050369","article-title":"Molecular biology of human papillomavirus infection and cervical cancer","volume":"110","author":"Doorbar","year":"2006","journal-title":"Clin. Sci. (Lond.)"},{"issue":"4","key":"10.1016\/j.humimm.2021.06.002_b0080","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ijc.30490","article-title":"A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of C\/EBP\u03b2 and OCT1 complex to chromatin","volume":"140","author":"Wu","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.humimm.2021.06.002_b0085","doi-asserted-by":"crossref","first-page":"e90090","DOI":"10.1371\/journal.pone.0090090","article-title":"Association of the polymorphisms in the Fas\/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4049\/jimmunol.170.1.132","article-title":"A Novel polymorphic CAAT\/enhancer-binding protein \u03b2 element in the fasl gene promoter alters fas ligand expression: a candidate background gene in african american systemic lupus erythematosus patients","volume":"170","author":"Wu","year":"2003","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.humimm.2021.06.002_b0095","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20050707","article-title":"FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer","volume":"202","author":"Sun","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.humimm.2021.06.002_b0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nri2233","article-title":"Creating immune privilege: active local suppression that benefits friends, but protects foes","volume":"8","author":"Mellor","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2021.06.002_b0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ygyno.2013.08.025","article-title":"Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape","volume":"131","author":"Conesa-Zamora","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.humimm.2021.06.002_b0110","doi-asserted-by":"crossref","unstructured":"Strizova Z, Kuchar M, Capkova J, Komarc M, Skrivan J, Bartunkova J. et al. Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response. Biomedicines 2021;9:402.","DOI":"10.3390\/biomedicines9040402"},{"issue":"1","key":"10.1016\/j.humimm.2021.06.002_b0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/14728222.2011.628937","article-title":"Targeting the fas\/FasL signaling pathway in cancer therapy","volume":"16","author":"Villa-Morales","year":"2012","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"10.1016\/j.humimm.2021.06.002_b0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7150\/jca.48120","article-title":"Genomic variants in Fas-mediated apoptosis pathway predict a poor response to platinum-based chemotherapy for Chinese gastric cancer patients","volume":"12","author":"Zhao","year":"2021","journal-title":"J. Cancer"},{"issue":"7","key":"10.1016\/j.humimm.2021.06.002_b0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"9430","key":"10.1016\/j.humimm.2021.06.002_b0130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","article-title":"The cervical cancer epidemic that screening has prevented in the UK","volume":"364","author":"Peto","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.humimm.2021.06.002_b0135","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/IGC.0000000000001216","article-title":"The european society of gynaecological oncology\/european society for radiotherapy and oncology\/european society of pathology guidelines for the management of patients with cervical cancer","volume":"28","author":"Cibula","year":"2018","journal-title":"Int. J Gynecol. Cancer"}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885921001336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885921001336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:54:24Z","timestamp":1759319664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885921001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0198885921001336"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2021.06.002","relation":{},"ISSN":["0198-8859"],"issn-type":[{"type":"print","value":"0198-8859"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between polymorphisms in the FAS\/FASL death receptor system and progression of low-grade precursor lesions infected with high-risk human papilloma virus","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}